Background: Gout is the most common inflammatory arthritis, with a rising incidence in the UK. Management guidelines have been updated and recommend lower thresholds for initiation of urate-lowering drugs. Our aim was to describe trends in admissions due to gout in England, with rheumatoid arthritis (RA) as a comparator, alongside prescribing trends for common gout medications. Methods: NHS Digital data were used to calculate hospital admission rates for gout and RA in adults aged over 20 years in England between April 2006 and March 2017. Primary care prescription data for commonly used gout therapies were considered for the same time period. Results: Between April 2006 and March 2017, a total of 56,664 admissions were recorded with gout as a primary diagnosis. The incidence rate of unplanned gout admissions increased by 59% between 2006 and 2017, from 7.9 to 12.5 admissions per 100,000 population; increasing as a proportion of all hospital admissions from 0.023% to 0.032%. Unplanned RA admissions decreased by 50% over the same time period, from 8.6 to 4.3 admissions per 100,000 population. The median length of stay for gout was 3.2 days; mean length of stay was 6.6 days (SD 0.52). Cumulatively, gout admissions accounted for 349,768 bed-days. Primary care prescriptions issued for allopurinol have risen since 2006, from 7387 to 12697 per 100,000 population (72% increase). Colchicine prescriptions increased from 394 to 1046 per 100,000 population over the same time period (166% increase). Prescriptions for febuxostat (launched in the UK in 2008, with prescription data available from 2010-2016) have increased 20-fold, from 15 to 300 per 100,000 population. Conclusion: Gout admissions in England are rising, accompanied by increasing prescription of gout therapies. Improvements in coding may explain part of the observed change; however, unplanned RA admissions have halved over the same time period. These data should be a call to arms for rheumatologists to ensure we aggressively manage this potentially curable disease. Introducing the concept of a door-to-needle time into acute gout management, coupled with early involvement of acute rheumatology services, has the potential to significantly reduce the cost burden of this king of diseases (A graph showing trends in admission incidence rates for gout and RA is available upon request). Disclosures: The authors have declared no conflicts of interest.
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